Abstract
Lactoferrin, a multifunctional protein with antimicrobial activity, is a component of the innate immune system. It may possibly prevent clinical isolates of Pseudomonas aeruginosa from developing biofilm, but this hypothesis is yet to be widely accepted. We evaluated the in vitro effects of lactoferrin on biofilm formation by various clinical isolates of P. aeruginosa using a modified method of the microtiter plate biofilm assay. Lactoferrin significantly inhibited biofilm formation in these isolates. The effect was the most marked at 2 mg/ml, which suggested that an optimal concentration of lactoferrin might exist. Lactoferrin inhibited biofilm formation in eight of nine clinical isolates after 1 day of incubation; however, the inhibitory effects were maintained until 7 days of incubation in only two of those eight strains. Suppression of biofilm formation may be caused by a mechanism that is independent of the bactericidal effects of lactoferrin because the number of viable bacteria was not influenced by lactoferrin under the experimental conditions. Supplementation of lactoferrin to preformed biofilm demonstrated a reduction in biofilm, which suggests that lactoferrin may have a destructive effect on biofilm. Pretreatment with ferric chloride partially restored biofilm formation, suggesting an iron-chelating action may be involved in the inhibitory mechanism of lactoferrin. These results suggest that lactoferrin provides inhibitory effects on biofilm formation in many clinical isolates of P. aeruginosa and that it may also have destructive effects on preformed biofilm, but further research using multiple clinical strains should be undertaken to clarify if those effects are universal.
Similar content being viewed by others
References
Koch C, Høiby N. Pathogenesis of cystic fibrosis. Lancet. 1993;341:1065–9.
Honma H, Yamanaka A, Tanimoto S, Tamura M, Chijimatsu Y, Kira S, et al. Diffuse panbronchiolitis. A disease of the transitional zone of the lung. Chest. 1983;83:63–9.
Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318–22.
Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science. 1998;280:295–8.
Wagner VE, Iglewski BH. Pseudomonas aeruginosa biofilms in CF infection. Clin Rev Allergy Immunol. 2008;35:124–34.
Costerton JW, Irvin RT, Cheng KJ. The bacterial glycocalyx in nature and disease. Annu Rev Microbiol. 1981;35:299–324.
Schwarzmann S, Boring JR. Antiphagocytic effect of slime from a mucoid strain of Pseudomonas aeruginosa. Infect Immun. 1971;3:762–7.
Stewart PS. A review of experimental measurements of effective diffusive permeabilities and effective diffusion coefficients in biofilms. Biotechnol Bioeng. 1998;59:261–72.
Orsi N. The antimicrobial activity of lactoferrin: current status and perspectives. Biometals. 2004;17:189–96.
Singh PK, Parsek MR, Greenberg EP, Welsh MJ. A component of innate immunity prevents bacterial biofilm development. Nature (Lond). 2002;417:552–5.
Merritt JH, Kadouri DE, O’Toole GA (2005) Growing and analyzing static biofilms. In: Coico R, Kowalik T, Quarles J, Stevenson B, Taylor R (eds) Current protocols in microbiology, vol 1. Wiley, Hoboken, pp 1B.1.1–1B.1.17.
Alugupalli KR, Kalfas S. Degradation of lactoferrin by periodontitis-associated bacteria. FEMS Microbiol Lett. 1996;145:209–14.
de Lillo A, Teanpaisan R, Fierro JF, Douglas CWI. Binding and degradation of lactoferrin by Porphyromonas gingivalis, Prevotella intermedia and Prevotella nigrescens. FEMS Immunol Med Microbiol. 1996;14:135–43.
Wakabayashi H, Yamauchi K, Kobayashi T, Yaeshima T, Iwatsuki K, Yoshie H. Inhibitory effects of lactoferrin on growth and biofilm formation of Porphyromonas gingivalis and Prevotella intermedia. Antimicrob Agents Chemother. 2009;53:3308–16.
Chierici R. Antimicrobial actions of lactoferrin. Adv Nutr Res. 2001;10:247–69.
Singh PK. Iron sequestration by human lactoferrin stimulates Pseudomonas aeruginosa surface motility and blocks biofilm formation. Biometals. 2004;17:267–70.
Banin EB, Vasil ML, Greenberg EP. Iron and Pseudomonas aeruginosa biofilm formation. Proc Natl Acad Sci USA. 2005;102:11076–81.
Ammons MCB, Ward LS, Fisher ST, Wolcott RD, James GA. In vitro susceptibility of established biofilms composed of clinical wound isolates of Pseudomonas aeruginosa treated with lactoferrin and xylitol. Int J Antimicrob Agents. 2009;33:230–6.
Wakabayashi H, Kuwata H, Yamauchi K, Teraguchi S, Tamura Y. No detectable transfer of dietary lactoferrin or its functional fragments to portal blood in healthy adult rats. Biosci Biotechnol Biochem. 2004;68:853–60.
Acknowledgments
The authors thank Mr. Hiroyuki Wakabayashi of Morinaga Milk Industry Co., Ltd., for the valuable advice he provided throughout the study.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Kamiya, H., Ehara, T. & Matsumoto, T. Inhibitory effects of lactoferrin on biofilm formation in clinical isolates of Pseudomonas aeruginosa . J Infect Chemother 18, 47–52 (2012). https://doi.org/10.1007/s10156-011-0287-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10156-011-0287-1